Enanta Pharmaceuticals Inc (fra:9EP) Share Price

Company Profile

Business description
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.
Contact
4 Kingsbury Avenue
WatertownMA02472
USA
T: +1 617 607-0800
E: [email protected]
https://www.enanta.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 September 2026
Employees
120

Recommended

Headwinds in listed energy stocks likely to have passed

Esther Holloway | 30 March 2026

Potential investors should remember that the company’s controlling shareholder can move markets with a few words.

Franco Granda | 30 March 2026

What we can and can’t learn from the top 20 most shorted ASX shares.

Tyger Fitzpatrick | 30 March 2026

Index	Last price	Change	% Change
All Ordinaries	8,683.90	11.50	0.13%
CAC 40	7,811.43	38.98	0.50%
DAX 40	22,716.40	153.52	0.68%
Dow JONES (US)	45,216.14	49.50	0.11%
FTSE 100	10,196.67	68.71	0.68%
HKSE	24,788.14	37.35	0.15%
NASDAQ	20,794.64	153.72	-0.73%
Nikkei 225	51,063.72	822.13	-1.58%
NZX 50 Index	12,912.11	163.19	1.28%
S&P 500	6,343.72	25.13	-0.39%
S&P/ASX 200	8,481.80	4.60	0.05%
SSE Composite Index	3,891.86	31.43	-0.80%